X

Trial Profile

Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

10 Jul 2021 Results evaluating the safety and maximum tolerated dose (MTD) of alisertib in combination with nab-paclitaxel and its preliminary efficacy in patients with refractory high-grade neuroendocrine tumours (NETs) published in the European Journal of Cancer
09 Jan 2018 Status changed from active, no longer recruiting to completed.
17 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com